Serbia gives Galenika sale another month
BELGRADE, April 30
BELGRADE, April 30 (Reuters) - Serbia on Tuesday extended for another month a deadline for bids for its indebted state-run drugmaker Galenika Pharmaceuticals, with the U.S.-based unit of Canada's Valeant Pharmaceuticals International so far the only potential partner.
The finance ministry said the new deadline was 4 p.m. (1400 GMT) on May 31, the third extension since offers were first invited on Jan. 14.
With a workforce of 2,700, the Belgrade-based Galenika has accumulated debt of about 170 million euros ($223 million), and needs about 50 million euros in additional capital in 2013.
Its sale is part of an effort by the government to offload a number of bloated, loss-making state enterprises to ease the burden on its budget.
Earlier in April, the finance ministry said the U.S.-based unit of Valeant was the only potential partner so far, having met all the conditions of the tender.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Target cyber breach hits 40 million payment cards at holiday peak |
- 'Duck Dynasty' anti-gay fallout sparks debate on religion, tolerance
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Zuckerberg to sell Facebook shares worth about $2.3 billion |